Pro Dex vs Utah Medical Products
PDEX and UTMD side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PDEX and UTMD compare
Pro Dex and Utah Medical Products are about the same size, with market caps of $216M and $234M.
On earnings, Pro Dex is cheaper: it trades at 18.6× trailing earnings, against 22.4× for Utah Medical Products.
Utah Medical Products pays a dividend yielding 1.7%; Pro Dex does not pay one.
Pro Dex scores higher on the StockData Score (18 against 10 for Utah Medical Products), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PDEX | UTMD |
|---|---|---|
| Size and price | ||
| Market cap | $216M | $234M |
| Share price | $67.42 | $73.63 |
| Change, 1 year | 101% | 28.7% |
| Change, 5 years | 230% | −36.3% |
| Beta (5Y) | 0.26 | 0.48 |
| Employees | 181 | 140 |
| StockData Score | ||
| Total score | 18 (better) | 10 |
| Valuation score | 2 | 3 (better) |
| Growth score | 4 (better) | 0 |
| Performance score | 6 (better) | 1 |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | 18.6× (better) | 22.4× |
| P/S | 2.7× (better) | 6.5× |
| P/B | 4.4× | 1.9× (better) |
| EV/EBITDA | 14.4× | 14.3× (better) |
| P/FCF | 20.2× (better) | 20.5× |
| PEG | 0.66 | – |
| FCF yield | 5.0% (better) | 4.9% |
| Fair value | $70.38 | $76.08 |
| Margin of safety | 4.2% (better) | 3.2% |
| Growth | ||
| Revenue growth (TTM) | 13.3% | – |
| Revenue growth, 5Y average | 15.3% (better) | −1.8% |
| Net income growth (TTM) | 7.5% | – |
| EPS growth (TTM) | 8.4% | – |
| EPS growth, 5Y average | 21.3% (better) | 3.4% |
| Profitability | ||
| Gross margin | 32.5% | 57.9% (better) |
| Operating margin | 16.8% | 28.4% (better) |
| Net margin | 15.1% | – |
| FCF margin | 13.4% | 31.7% (better) |
| Return on equity | 26.5% | – |
| Return on invested capital | 24.1% (better) | 23.9% |
| Financial health | ||
| Debt / equity | 0.25 | 0.00 (better) |
| Net debt / EBITDA | −0.05 | −8.51 |
| Interest coverage | 15.4× | – |
| Current ratio | 4.19 | 48.62 (better) |
| Altman Z-score | 7.91 | 58.39 (better) |
| Piotroski F-score | 6 | – |
| Dividends and buybacks | ||
| Dividend yield | – | 1.7% |
| Buyback yield | – | 0.79% |
| Shareholder yield | 0.00% | 2.5% (better) |
| Ownership | ||
| Held by institutions | 22.9% | 72.8% |
| Held by insiders | 45.7% | 7.3% |
| Insider net buying, 12 months | −$2.0M | $66.8K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 15.6% | 5.1% |
Go deeper
- PDEX stock overview
- PDEX income statement
- PDEX valuation and score
- UTMD stock overview
- UTMD income statement
- UTMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.